Clinical trial NCT06308510: Detection of Aneuploidy in Cell Free DNA to Improve the Sensitivity of Diagnostic Peritoneal Lavage in Gastric Cancer
Official title: Detection of Aneuploidy in Cell Free DNA to Improve the Sensitivity of Diagnostic Peritoneal Lavage in Gastric Cancer
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Gastric Cancer
Keywords: peritoneal metastasis
cfDNA
Lead sponsor: Erasmus Medical Center
Sponsor class: OTHER
First posted: 2024-03-13
Enrollment: 63
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Gastric cancer patients:

Patients who will undergo DLS for GC or GEJ carcinoma

Non-cancer controls:

Operable patients who will undergo a planned diagnostic laparoscopy for a benign indication (bariatric or gallbladder disease);

Brief summary: Aneuploidy may be used as a more sensitive diagnostic tool to detect peritoneal metastasis compared to conventional cytology and imaging techniques. Our aim is to establish whether aneuploidy as detected in cfDNA (as a measure for ctDNA) in PLF of patients with GC may hold value as an additional staging and tumor evaluation method in GC patients.

Detailed description: To ensure the appropriate treatment strategy for gastric cancer, various methods are employed to determine clinical disease stage. Peritoneal metastases are common in gastric cancer, but accurately detecting these peritoneal metastasis using conventional imaging techniques remains challenging. To increase the sensitivity of staging when gastric cancer appears resectable on CT imaging, a diagnostic peritoneal staging laparoscopy (DLS) is performed. During DLS, the abdominal cavity is inspected for the presence of macroscopic peritoneal metastasis. Furthermore, a peritoneal lavage with saline is performed, and the collected fluid is examined by a pathologist for the presence of cancer cells. However, the sensitivity of this cytological evaluation is limited, and as a result of false negative results, patients currently unjustly undergo treatment with curative intent, exposing them to the risks and side-effects of surgery and intensive perioperative chemotherapy. A more sensitive technique to detect peritoneal metastases during staging would lead to better personalized treatment; less toxic palliative treatment, or more intensive peritoneum-directed therapy in a trial setting in selected patients.

A more sensitive diagnostic tool to detect peritoneal metastasis compared to conventional cytology and imaging techniques may be the detection of ctDNA. One way to detect ctDNA is by assessing aneuploidy, as its presence reflects the fraction of circulating tumor DNA within cell-free DNA.

Objective:To assess the value of ctDNA detection using aneuploidy analyses of peritoneal lavage fluid using mFAST-SeqS method in a prospective cohort of patients with gastric cancer who undergo a staging laparoscopy, in addition to the current staging methods (cytology, radiology, laparoscopy) and blood ctDNA analysis.

Eligibility criteria: Gastric cancer patients:

Inclusion Criteria:

* Age ≥18 years old;
* Written informed consent according to the ICH-GCP and national/local regula-tions.

Exclusion Criteria:

- Language difficulty, dementia or altered mental status prohibiting the under-standing and giving of informed consent.

non-cancer controls:

Inclusion criteria:

* Operable patients who will undergo a planned diagnostic laparoscopy for a benign indication bariatric or gallbladder disease);
* Age ≥18 years old;
* Written informed consent according to the ICH-GCP and national/local regulations.

Exclusion criteria:

* Active inflammation or infection;
* Subjects with previous malignancies are excluded unless a complete remission was achieved at least 5 years prior to study entry (exceptions include but are not limited to, non-melanoma skin cancers; in situ bladder cancer, or in situ co-lon cancers; in situ cervical cancers/dysplasia; or breast carcinoma in situ).

Primary outcomes:
measure: Sensitivity mFast-SeqS
timeFrame: 4 years
Secondary outcomes:
measure: DFS
timeFrame: 2 years
measure: Concordance detection rates peritoneal dissemination
timeFrame: 4 years
Other outcomes:
Locations:
city: Rotterdam
country: Netherlands
facility: Erasmus MC
Study officials:
affiliation: Erasmus Medical Center
name: Bianca Mostert, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Erasmus Medical Center
name: Sjoerd Lagarde, MD
role: PRINCIPAL_INVESTIGATOR
References: